Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Japan's 1st GLP-1 Analogue Victoza: Novo Nordisk
February 1, 2010
- JSMI Recommends 29 More APIs for Switching to OTC Status
February 1, 2010
- Combination of ARB + Ca Blocker Rezaltas: Daiichi Sankyo
February 1, 2010
- Humira, Remicade to Be Excluded from DPC Payment When Used for Psoriasis
February 1, 2010
- Notification Issued for Proper Use of Afinitor
February 1, 2010
- Higher-Strength Metformin Preparation Metgluco Tab 250 mg: DSP
February 1, 2010
- Remicade for Psoriasis: MTPC
February 1, 2010
- Bendamustine Added to NCCN GLs as First-Line Therapy: SymBio
February 1, 2010
- Antidepressant Cymbalta: Shionogi
February 1, 2010
- Anti-Flu Agent Rapiacta Included in NHI Price List
February 1, 2010
- Greater Importance Put on Surgery in Insurance Coverage
February 1, 2010
- Xalacom for Glaucoma: Pfizer
February 1, 2010
- Korosho to Ask Companies to Comment on the Need for Listed Unapproved Drugs
February 1, 2010
- Cymbalta to Drive Shionogi's Business in Mid-Term: Ms Sawada
February 1, 2010
- Sugammadex for Reversal of Neuromuscular Blockade: Schering-Plough
February 1, 2010
- New Premium to Allow Chuikyo to Interfere with Company Management : Prof. Tsutsumi
February 1, 2010
- Takeda to More Actively Develop Business in Emerging Markets: President Hasegawa
February 1, 2010
- Anti-Emetic Aloxi: Taiho
February 1, 2010
- New Premium to Make Drugs More Liable to Re-Pricing: Mr Nishiyama
February 1, 2010
- Banyu, Schering-Plough to Copromote 7 Products in Preparation for Merger
February 1, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…